NuCana (NCNA) Cash from Investing Activities (2017 - 2025)
NuCana (NCNA) reported Cash from Investing Activities of $178242.3 for Q4 2025, up 531.24% on a YoY basis from $28237.0 in Q4 2024, and up 106.4% sequentially from $86359.2 in Q3 2025.
NuCana (NCNA) Cash from Investing Activities (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Cash from Investing Activities data on file, last reported at $178242.3 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities rose 531.24% year-over-year to $178242.3; the trailing twelve-month figure through Dec 2025 stood at $316225.9 (up 212.72% YoY), and the FY2025 full-year result was $209643.1, up 107.6% from the prior year.
- Cash from Investing Activities rose to $178242.3 in Q4 2025, from $86359.2 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $3.4 million in Q3 2023 to a low of -$3.9 million in Q3 2021.
- A 5-year average of -$42517.4 and a median of $28509.2 in 2024 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities sank 406.97% in 2021 and soared 3249.53% in 2023, its largest moves.
- Tracing NCNA's Cash from Investing Activities over 5 years: stood at -$624128.9 in 2021, then surged by 130.07% to $187668.5 in 2022, then sank by 64.95% to $65781.0 in 2023, then slumped by 57.07% to $28237.0 in 2024, then surged by 531.24% to $178242.3 in 2025.
- Business Quant data shows NCNA's Cash from Investing Activities at $178242.3 in Q4 2025, $86359.2 in Q3 2025, and $28237.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,380.63 Bn | 66,380.34 Bn | - | - |
| 2 | Nanobiotix | 1,910.39 Bn | 1,910.33 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.95 Bn | 466.16 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.58 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | -25.54 Mn |
| 10 | NuCana | 15.22 Bn | 15.19 Bn | - | 178,242.27 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 178,242.27 |
| Dec 31, 2025 | 178,242.27 |
| Sep 30, 2025 | 86,359.18 |
| Sep 30, 2025 | 86,359.18 |
| Dec 31, 2024 | 28,237.04 |
| Dec 31, 2024 | 28,237.04 |
| Sep 30, 2024 | 23,387.40 |
| Sep 30, 2024 | 23,387.40 |
| Jun 30, 2024 | -5,048.88 |
| Jun 30, 2024 | -5,048.88 |
| Mar 31, 2024 | 54,546.28 |
| Mar 31, 2024 | 54,546.28 |
| Dec 31, 2023 | 65,781.05 |
| Dec 31, 2023 | 65,781.05 |
| Sep 30, 2023 | 3.36 Mn |
| Sep 30, 2023 | 3.36 Mn |
| Jun 30, 2023 | 28,781.35 |
| Jun 30, 2023 | 28,781.35 |
| Mar 31, 2023 | 198,128.05 |
| Mar 31, 2023 | 198,128.05 |